Fate Therapeutics Inc (FATE)

Jan 31, 2025

Fate Therapeutics' SWOT analysis: stock poised for catalysts amid clinical progress - MSN

Jan 31, 2025

Jan 28, 2025

Fate Therapeutics Inc (NASDAQ: FATE) Is A Buzzing Hot Stock - Stocks Register

Jan 28, 2025

Jan 25, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Assenagon Asset Management S.A. - Defense World

Jan 25, 2025

Jan 23, 2025

Equities Analysts Offer Predictions for FATE FY2025 Earnings - Defense World

Jan 23, 2025

Jan 22, 2025

Research Analysts Set Expectations for FATE FY2025 Earnings - MarketBeat

Jan 22, 2025

Jan 22, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Jan 22, 2025

Jan 22, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

Jan 22, 2025

Jan 19, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Update - MarketBeat

Jan 19, 2025

Jan 16, 2025

JPMorgan Chase & Co. Has $6.43 Million Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jan 16, 2025

Jan 16, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Bought by JPMorgan Chase & Co. - MarketBeat

Jan 16, 2025

Jan 15, 2025

Day 0 of Loss Streak for Fate Therapeutics Stock with 0% Return (vs. -20% YTD) [1/22/2025] - Trefis

Jan 15, 2025

Jan 14, 2025

Fate Therapeutics' SWOT analysis: stock poised for growth amid clinical progress - Investing.com

Jan 14, 2025

Jan 13, 2025

Fate Therapeutics’ chief legal officer Cindy Tahl sells $8,763 in stock - Investing.com Nigeria

Jan 13, 2025

Jan 13, 2025

Fate Therapeutics CEO sells shares worth $13,405 By Investing.com - Investing.com Canada

Jan 13, 2025

Jan 13, 2025

Fate Therapeutics' chief legal officer Cindy Tahl sells $8,763 in stock By Investing.com - Investing.com South Africa

Jan 13, 2025

Jan 13, 2025

Fate Therapeutics executive sells $9,269 in common stock By Investing.com - Investing.com Canada

Jan 13, 2025

Jan 13, 2025

Fate Therapeutics' chief legal officer Cindy Tahl sells $8,763 in stock - Investing.com Canada

Jan 13, 2025

Jan 13, 2025

Insider Selling: Fate Therapeutics, Inc. (NASDAQ:FATE) CEO Sells $13,405.70 in Stock - MarketBeat

Jan 13, 2025

Jan 13, 2025

Barclays PLC Has $1.49 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jan 13, 2025

Jan 07, 2025

Fate Therapeutics, Inc. Announces Retirement of J. Scott Wolchko as Treasurer, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer - Marketscreener.com

Jan 07, 2025

Jan 07, 2025

Fate Therapeutics appoints new CEO, enters advisory pact By Investing.com - Investing.com Canada

Jan 07, 2025

Jan 06, 2025

Fate Therapeutics appoints new CEO, enters advisory pact - Investing.com

Jan 06, 2025

Jan 06, 2025

Jane Street Group LLC Sells 69,867 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jan 06, 2025

Jan 03, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jan 03, 2025

Jan 03, 2025

Geode Capital Management LLC Acquires 10,863 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jan 03, 2025

Dec 31, 2024

Stifel Financial Corp Sells 17,391 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 31, 2024

Dec 31, 2024

Franklin Resources Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 31, 2024

Dec 29, 2024

Barclays PLC Buys 301,389 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 29, 2024

Dec 28, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World

Dec 28, 2024

Dec 28, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $6.75 Average Target Price from Brokerages - MarketBeat

Dec 28, 2024

Dec 27, 2024

Redmile Group, LLC Reduces Stake in Fate Therapeutics Inc - GuruFocus.com

Dec 27, 2024

Dec 26, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Director Acquires $668,579.52 in Stock - MarketBeat

Dec 26, 2024

Dec 26, 2024

Redmile group sells $573,943 in Fate Therapeutics stock By Investing.com - Investing.com South Africa

Dec 26, 2024

Dec 26, 2024

Redmile group sells $573,943 in Fate Therapeutics stock - Investing.com

Dec 26, 2024

Dec 24, 2024

State Street Corp Sells 85,715 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 24, 2024

Dec 24, 2024

Fate Therapeutics stock hits 52-week low at $1.59 By Investing.com - Investing.com Canada

Dec 24, 2024

Dec 21, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $497,000 Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 21, 2024

Dec 19, 2024

Critical Survey: Fate Therapeutics (NASDAQ:FATE) versus HilleVax (NASDAQ:HLVX) - Defense World

Dec 19, 2024

Dec 18, 2024

Fmr LLC Buys 46,892 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 18, 2024

Dec 17, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Sees Significant Growth in Short Interest - MarketBeat

Dec 17, 2024

Dec 16, 2024

FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Marketscreener.com

Dec 16, 2024

Dec 16, 2024

Charles Schwab Investment Management Inc. Has $2.67 Million Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 16, 2024

Dec 15, 2024

Fate Therapeutics' SWOT analysis: cell therapy stock shows promise amid risks - Investing.com

Dec 15, 2024